Citations

Showing 10 of 108104 citations.

BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension
Spikes, Leslie , Eggert, Michael, Johri, Shilpa , Joly, Joanna M., Mehta, J.P. , Palevsky, Harold I. , Ramani, Gautam , Restrepo‐Jaramillo, Ricardo, Sahay, Sandeep , Shah, Trushil , Miceli, Melissa, Smith, Peter , Shapiro, Shelley, Spikes, Leslie A , Sahay, Sandeep , Bajwa, Abubakr A. , Burger, Charles D. , Desai, Sapna V., El‐Kersh, Karim , Fisher, Micah R., Deng, Chunqin

Mayo Clinic

Pulmonary Circulation | March 23, 2022 | Volume: 12 | Issue: 2 | Pages: No page available

10.1002/pul2.12063 | PMID 35514770 Get It

AbstractInhaled treprostinil is an approved therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease in the United States. Studies have confirmed the robust benefits and safety of nebulized inhaled treprostinil, but it requires a time investment for nebulizer preparation, maintenance, and treatment. A small, portable treprostinil dry powder inhaler has been developed for the treatment of PAH. The primary objective of this study was to evaluate the safety and tolerability of treprostinil inhalation powder (TreT) in patients currently treated with treprostinil inhalation solution. Fifty‐one patients on a stable dose of treprostinil inhalation solution enrolled and transitioned to TreT at a corresponding dose. Six‐minute walk distance (6MWD), device preference and satisfaction (Preference Questionnaire for Inhaled Treprostinil Devices [PQ‐ITD]), PAH Symptoms and Impact (PAH‐SYMPACT®) questionnaire, and systemic exposure and pharmacokinetics for up to 5 h were assessed at baseline for treprostinil inhalation solution and at Week 3 for TreT. Adverse events (AEs) were consistent with studies of inhaled treprostinil in patients with PAH, and there were no study drug‐related serious AEs. Statistically significant improvements occurred in 6MWD, PQ‐ITD, and PAH‐SYMPACT. Forty‐nine patients completed the 3‐week treatment phase and all elected to participate in an optional extension phase. These results demonstrate that, in patients with PAH, transition from treprostinil inhalation solution to TreT is safe, well‐tolerated, and accompanied by statistically significant improvements in key clinical assessments and patient‐reported outcomes with comparable systemic exposure between the two formulations at evaluated doses (trial registration: clinicaltrials.gov identifier: NCT03950739).
Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation
Warsame, Rahma , Buadi, Frances, Hayman, Suzanne R. , Kapoor, Prashant , Kourelis, Taxiarchis , Kumar, Shaji , Lacy, Martha Q. , Gertz, Morie A. , Muchtar, Eli , Dispenzieri, Angela , Gonsalves, Wilson I. , Dingli, David , Hogan, William J.

Mayo Clinic

No container title available | March 23, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1454378/v1 Get It

Abstract Introduction: There is evidence that lack of a social network is a link to inferior outcomes in cancer patients. Mayo clinic performs all its stem cell transplants for multiple myeloma patients as an outpatient. This requires a full-time chaperone or caregiver for the duration of the transplant. Patients who do not have a caregiver are hospitalized for the duration of the transplant. In this study we compared outcomes between patients hospitalized for the entire transplant and those who have a caregiver and are initially managed as an outpatient.Materials and methods: All patients with multiple myeloma transplanted at the Mayo Clinic in Rochester Minnesota between 1/1/2000 and 12/31/2019 were included for analysis. Patient had to have been transplanted within 12 months of the original diagnosis. The definition of inpatient transplantation was hospitalization prior to day 0 of transplantation for conditioning and continued hospitalization until evidence of neutrophil engraftment occurred.Results: There were 41 patients who were considered inpatient transplants and 2103 that were outpatient transplants. The patients were well balanced for age, sex, serum creatinine, and international stage at diagnosis. For inpatient transplants the median days in the hospital was 21 (interquartile range 18 to 28). For outpatient transplants the median number of days in the hospital was 0 (interquartile range 0 to 6). Relapse free survival was not significantly different between the 2 groups, but overall survival was 95 versus 58 months favoring those that had transplantation as an outpatient (p=.0008). Conclusion: There appears to be in association between myeloma patients that lack a caregiver and require inpatient stem cell transplantation and overall survival.
A simulated comparison of lung tumor target verification using stereoscopic tomosynthesis or radiography
Hsieh, Scott S. , Ng, Lydia W., Lee, Percy , Cao, Minsong

Mayo Clinic

Medical Physics | March 23, 2022 | Volume: 49 | Issue: 5 | Pages: 3041-3052

10.1002/mp.15634 | PMID 35319790 Get It

AbstractPurposeMobile lung tumors are increasingly being treated with ablative radiotherapy, for which precise motion management is essential. In‐room stereoscopic radiography systems are able to guide ablative radiotherapy for stationary cranial lesions but not optimally for lung tumors unless fiducial markers are inserted. We propose augmenting stereoscopic radiographic systems with multiple small x‐ray sources to provide the capability of imaging with stereoscopic, single frame tomosynthesis.MethodsIn single frame tomosynthesis, nine x‐ray sources are placed in a 3 × 3 configuration and energized simultaneously. The beams from these sources are collimated so that they converge on the tumor and then diverge to illuminate nine non‐overlapping sectors on the detector. These nine sector images are averaged together and filtered to create the tomosynthesis effect. Single frame tomosynthesis is intended to be an alternative imaging mode for existing stereoscopic systems with a field of view that is three times smaller and a temporal resolution equal to the frame rate of the detector. We simulated stereoscopic tomosynthesis and radiography using Monte Carlo techniques on 60 patients with early‐stage lung cancer from the NSCLC‐Radiomics dataset. Two board‐certified radiation oncologists reviewed these simulated images and rated them on a 4‐point scale (1: tumor not visible; 2: tumor visible but inadequate for motion management; 3: tumor visible and adequate for motion management; 4: tumor visibility excellent). Each tumor was independently presented four times (two viewing angles from radiography and two viewing angles from tomosynthesis) in a blinded fashion over two reading sessions.ResultsThe fraction of tumors that were rated as adequate or excellent for motion management (scores 3 or 4) from at least one viewing angle was 53% using radiography and 90% using tomosynthesis. From both viewing angles, the corresponding fractions were 7% for radiography and 48% for tomosynthesis. Readers agreed exactly on 62% of images and within 1 point on 98% of images. The acquisition technique was estimated to be 75 mAs at 120 kVp per treatment fraction assuming one verification image per breath, approximately one order of magnitude less than a standard dose cone beam CT.Conclusions Stereoscopic tomosynthesis may provide a noninvasive, low dose, intrafraction motion verification technique for lung tumors treated by ablative radiotherapy. The system architecture is compatible with real‐time video capture at 30 frames per second. Simulations suggest that most, but not all, lung tumors can be adequately visualized from at least one viewing angle.
Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1
Sethi, Sanjeev , Madden, Benjamin, Moura, Marta Casal , Nasr, Samih H., Klomjit, Nattawat, Gross, LouAnn, Negron, Vivian, Charlesworth, M. Cristine, Alexander, Mariam P. , Leung, Nelson , Haas, Mark, Klomjit, Nattawat , Casal Moura, Marta , Specks, Ulrich , Leung, Nelson , Alexander, Mariam P , Klomjit, Nattawat , Sethi, Sanjeev , Madden, Benjamin, Nasr, Samih H., Gross, LouAnn, Negron, Vivian, Charlesworth, M. Cristine, Fervenza, Fernando C , Haas, Mark

Mayo Clinic

Journal of the American Society of Nephrology | March 23, 2022 | Volume: 33 | Issue: 5 | Pages: 1033-1044

10.1681/asn.2021111488 | PMID 35321939 Get It

Background Membranous nephropathy (MN) is a common cause of proteinuria in patients receiving a hematopoietic stem cell transplant (HSCT). The target antigen in HSCT-associated MN is unknown. Methods We performed laser microdissection and tandem mass spectrometry (MS/MS) of glomeruli from 250 patients with PLA2R-negative MN to detect novel antigens in MN. This was followed by immunohistochemical (IHC)/immunofluorescence (IF) microscopy studies to localize the novel antigen. Western blot analyses using serum and IgG eluted from frozen biopsy specimen to detect binding of IgG to new 'antigen'. Results MS/MS detected a novel protein, protocadherin FAT1 (FAT1), in nine patients with PLA2R-negative MN. In all nine patients, MN developed after allogeneic HSCT (Mayo Clinic discovery cohort). Next, we performed MS/MS in five patients known to have allogeneic HSCT-associated MN (Cedar Sinai validation cohort). FAT1 was detected in all five patients by MS/MS. The total spectral counts for FAT1 ranged from 8 to 39 (mean±SD, 20.9±10.1). All 14 patients were negative for known antigens of MN, including PLA2R, THSD7A, NELL1, PCDH7, NCAM1, SEMA3B, and HTRA1. Kidney biopsy specimens showed IgG (2 to 3+) with mild C3 (0 to 1+) along the GBM; IgG4 was the dominant IgG subclass. IHC after protease digestion and confocal IF confirmed granular FAT1 deposits along the GBM. Lastly, Western blot analyses detected anti-FAT1 IgG and IgG4 in the eluate obtained from pooled frozen kidney biopsy tissue and in the serum of those with FAT1-asssociated MN, but not from those with PLA2R-associated MN. Conclusions FAT1-associated MN appears to be a unique type of MN associated with HSCT. FAT1-associated MN represents a majority of MN associated with HSCT.
Selective kidney targeting increases the efficacy of mesenchymal stromal/stem cells for alleviation of murine stenotic‐kidney senescence and damage
Kim, Seo Rin , Chen, Xiaojun , Zhu, Xiangyang , Kirkland, James L. , Lerman, Lilach O. , Jiang, Kai , Tchkonia, Tamara, Lerman, Lilach O , Jiang, Kai, Puranik, Amrutesh S. , Lerman, Amir , Tchkonia, Tamar

Mayo Clinic

Journal of Tissue Engineering and Regenerative Medicine | March 23, 2022 | Volume: 16 | Issue: 6 | Pages: 550-558

10.1002/term.3299 | PMID 35319825 Get It

Pseudoaneurysm of the Dorsalis Pedis Artery Following Open Reduction and Internal Fixation of a Second Metatarsal Fracture: A Case Study
Kvas, Stephanie P., Jorgensen, Scott F.

Mayo Clinic

Journal of the American Podiatric Medical Association | March 23, 2022 | Volume: 112 | Issue: 6 | Pages: No page available

10.7547/20-201 | PMID 36459069 Get It

Pseudoaneurysms are created by a traumatic or iatrogenic perforation of an artery, resulting in accumulation of blood between the two outermost layers of a blood vessel, the tunica media and tunica adventitia. Pedal artery pseudoaneurysms are an extremely uncommon complication of foot and ankle surgery; therefore, few cases have been reported in the literature. Early diagnosis is important to ensure timely treatment of this condition. Once clinical suspicion has been established, urgent referral to the vascular surgery clinic for prompt surgical evaluation is required to prevent potentially harmful sequelae. We present the case of a 70-year-old woman who developed a pseudoaneurysm of the dorsalis pedis artery 33 days after undergoing open reduction and internal fixation of a second metatarsal fracture. Her treatment included urgent referral to the vascular surgery clinic with subsequent surgical repair of the pseudoaneurysm by means of ligation of the medial dorsal branch of the dorsalis pedis artery. At 10-month follow-up, she denied any pain, sensory deficits, or functional disability and had returned to all preinjury activities, with no recurrence of the pseudoaneurysm. Our case study demonstrates early diagnosis and successful treatment of a pseudoaneurysm of the dorsalis pedis artery that developed shorty after open reduction and internal fixation of a second metatarsal fracture.
A transcriptomics-guided drug target discovery strategy identifies receptor ligands for lung regeneration
Wu, Xinhui , Bos, I. Sophie T., Conlon, Thomas M. , Ansari, Meshal , Verschut, Vicky, Koog, Luke van der , Verkleij, Lars A., D’Ambrosi, Angela, Matveyenko, Aleksey V. , Schiller, Herbert B. , Königshoff, Mélanie , Schmidt, Martina , Kistemaker, Loes , van der Koog, Luke , Matveyenko, Aleksey V , Yildirim, Ali Önder , Gosens, Reinoud , Gosens, Reinoud

Mayo Clinic

Science Advances | March 23, 2022 | Volume: 8 | Issue: 12 | Pages: No page available

10.1126/sciadv.abj9949 | PMID 35319981 Get It

Currently, there is no pharmacological treatment targeting defective tissue repair in chronic disease. Here, we used a transcriptomics-guided drug target discovery strategy using gene signatures of smoking-associated chronic obstructive pulmonary disease (COPD) and from mice chronically exposed to cigarette smoke, identifying druggable targets expressed in alveolar epithelial progenitors, of which we screened the function in lung organoids. We found several drug targets with regenerative potential, of which EP and IP prostanoid receptor ligands had the most profound therapeutic potential in restoring cigarette smoke–induced defects in alveolar epithelial progenitors in vitro and in vivo. Mechanistically, we found, using single-cell RNA sequencing analysis, that circadian clock and cell cycle/apoptosis signaling pathways were differentially expressed in alveolar epithelial progenitor cells in patients with COPD and in a relevant model of COPD, which was prevented by prostaglandin E2 or prostacyclin mimetics. We conclude that specific targeting of EP and IP receptors offers therapeutic potential for injury to repair in COPD.
Antithrombin Replacement and Extracorporeal Membrane Oxygenation: The time is ripe for a Simpler Solution
Seelhammer, Troy G. , Hamzah, Mohammed , Wieruszewski, Patrick M. , Wieruszewski, Patrick M , Hamzah, Mohammed

Mayo Clinic

ASAIO Journal | March 23, 2022 | Volume: 68 | Issue: 10 | Pages: e166-e167

10.1097/mat.0000000000001704 | PMID 35731962 Get It

Thymic Mucoepidermoid Carcinoma
Murase, Takayuki, Nakano, Satsuki, Sakane, Tadashi, Domen, Hiromitsu, Chiyo, Masako, Nagasaka, Satoshi, Tanaka, Michio, Kawahara, Yutaka, Toishi, Masayuki, Tanaka, Takuji, Nakamura, Shota, Sawabata, Noriyoshi, Okami, Jiro, Mukaida, Hidenori, Tzankov, Alexandar, Szolkowska, Malgorzata, Porubsky, Stefan, Marx, Alexander, Roden, Anja C., Inagaki, Hiroshi, Tzankov, Alexandar , Porubský, Štefan , Tzankov, Alexandar , Murase, Takayuki, Nakano, Satsuki, Sakane, Tadashi , Domen, Hiromitsu , Chiyo, Masako, Nagasaka, Satoshi, Tanaka, Michio, Kawahara, Yutaka, Toishi, Masayuki, Tanaka, Takuji, Nakamura, Shota, Sawabata, Noriyoshi, Okami, Jiro, Mukaida, Hidenori, Szolkowska, Malgorzata, Marx, Alexander, Roden, Anja C., Inagaki, Hiroshi

Mayo Clinic

American Journal of Surgical Pathology | March 23, 2022 | Volume: 46 | Issue: 8 | Pages: 1160-1169

10.1097/pas.0000000000001886 | PMID 35319525 Get It

Thymic mucoepidermoid carcinoma (MEC) is a rare tumor, and its characteristics remain to be clarified. Here we investigated 20 cases of thymic MEC to systematically characterize its clinical, histopathologic, and molecular features. The median age of the patients was 56 years (range, 19 to 80 y), there was a slight male predilection (3:2), and 44% of the patients were asymptomatic at diagnosis. The median tumor size was 6.8 cm in diameter, 55% were pT1 tumors, and 50% were TNM stage I tumors. When 4 tumor grading systems for salivary MEC (Armed Forces Institutes of Pathology, Brandwein, modified Healey, and the Memorial Sloan-Kettering) were employed, low-grade, intermediate-grade, and high-grade tumors accounted for 35% to 70%, 5% to 25%, and 25% to 50%, respectively. Many histologic variants were noted, and 70% of the cases were classified as nonclassic variants. MAML2 rearrangement was detected in 56% of cases, and the fusion partner was CRTC1 in all cases. CRTC1-MAML2 fusion was associated with lower pT classification and lower TNM stage. The overall survival rate of all patients was 69% and 43% at 5 and 10 years, respectively. Worse overall survival was associated with higher pT stage, higher TNM stage, residual tumors, greater tumor size, high-grade tumor histology (Armed Forces Institutes of Pathology and Memorial Sloan-Kettering, but not the other 2), and with the absence of CRTC1-MAML2 fusion. Of note, none of the patients with CRTC1-MAML2 fusion-positive tumors died during the follow-up. In conclusion, the clinicopathologic and molecular findings of thymic MEC presented here are expected to contribute to the management of this rare tumor.
Correspondence on “Unplanned readmission after carotid stenting versus endarterectomy: analysis of the United States Nationwide Readmissions Database" by Nazari et al
Ghozy, Sherief , Dmytriw, Adam A. , Kadirvel, Ramanathan , Kallmes, David F. , Azzam, Ahmed Y , Ghozy, Sherief , Dmytriw, Adam A , Kadirvel, Ram , Kallmes, Kevin M

Mayo Clinic

Journal of NeuroInterventional Surgery | March 23, 2022 | Volume: 15 | Issue: 3 | Pages: e1-e1

10.1136/neurintsurg-2022-018838 | PMID 35321868 Get It